RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mithra Pharmaceuticals Stock

Mithra Pharmaceuticals P/S 2024

Mithra Pharmaceuticals P/S

0.23

Ticker

MITRA.BR

ISIN

BE0974283153

WKN

A14V4E

As of Sep 6, 2024, Mithra Pharmaceuticals's P/S ratio stood at 0.23, a -94.13% change from the 3.92 P/S ratio recorded in the previous year.

The Mithra Pharmaceuticals P/S history

Mithra Pharmaceuticals Aktienanalyse

What does Mithra Pharmaceuticals do?

Mithra Pharmaceuticals SA is a Belgian pharmaceutical company specializing in women's health and hormone therapy. The company was founded in 1999 by François Fornieri and Jean-Michel Foidart and has since become a major player in women's healthcare. Its unique business model covers the entire value chain of the pharmaceutical industry, including research and development, production, distribution, and marketing of its own products. Mithra Pharmaceuticals SA collaborates with other pharmaceutical companies, universities, and public research institutions worldwide, aiming to offer innovative products and services based on new technologies and scientific knowledge. The company's divisions include hormone therapy, contraception, gynecology, and dermatology, providing a wide range of products and services tailored to women's needs. One of its notable products is the Estetrol patch, a safe and effective contraceptive containing a natural estrogen hormone produced during pregnancy. In gynecology, Mithra Pharmaceuticals SA offers products for the treatment of menstrual disorders, endometriosis, and vaginal dryness, such as the Estelle pill concept, which combines contraception and hormone regulation. In dermatology, the company provides skincare products based on natural ingredients, specifically designed for women with sensitive skin or skin issues. Overall, Mithra Pharmaceuticals SA focuses on meeting the needs of women and has a history of adapting to market conditions and offering innovative products and services. With its global presence and innovative products, Mithra Pharmaceuticals SA is well-positioned for future success. Mithra Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Mithra Pharmaceuticals's P/S Ratio

Mithra Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Mithra Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Mithra Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Mithra Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Mithra Pharmaceuticals stock

What is the price-to-earnings ratio of Mithra Pharmaceuticals?

The price-earnings ratio of Mithra Pharmaceuticals is currently 0.23.

How has the price-earnings ratio of Mithra Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Mithra Pharmaceuticals has increased by -94.13% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Mithra Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Mithra Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Mithra Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Mithra Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Mithra Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Mithra Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Mithra Pharmaceuticals?

Some factors that influence the price-earnings ratio of Mithra Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Mithra Pharmaceuticals pay?

Over the past 12 months, Mithra Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mithra Pharmaceuticals is expected to pay a dividend of 0 EUR.

What is the dividend yield of Mithra Pharmaceuticals?

The current dividend yield of Mithra Pharmaceuticals is .

When does Mithra Pharmaceuticals pay dividends?

Mithra Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mithra Pharmaceuticals?

Mithra Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Mithra Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mithra Pharmaceuticals located?

Mithra Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mithra Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mithra Pharmaceuticals from 9/6/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/6/2024.

When did Mithra Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/6/2024.

What was the dividend of Mithra Pharmaceuticals in the year 2023?

In the year 2023, Mithra Pharmaceuticals distributed 0 EUR as dividends.

In which currency does Mithra Pharmaceuticals pay out the dividend?

The dividends of Mithra Pharmaceuticals are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mithra Pharmaceuticals

Our stock analysis for Mithra Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mithra Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.